The Early Drug Development Summit is happening this week in Berlin, Germany, and it brings early drug developers together to discuss maximizing drug investments, toxicology, safety and biomarkers. The summit addresses the strategies and tools to fully optimize the early drug development trajectory in order to bring safe, effective and commercially viable drugs to market faster whilst achieving regulatory approval.

Frederik Deroose, CEO of Asclepia and consultant for Assay Depot will be presenting December 4th at 14:00 at the Early Drug Development Summit.


 Frederik will discuss Assay Depot’s virtual platform and how it is used to outsource early development processes and efficiently collaborate with CROs. Frederik has first hand experience of the value of Assay Depot’s platform; both in large pharma (sharing his experiences in building a private exchange for J&J) and for small companies like Asclepia. Furthermore, the presentation will highlight the following:

·    Effectively negotiating strategies to ensure a fair deal for R&D processes

·    Using virtual outsourcing to make tactical partnering decisions by assessing internal resources

·    Determining overall costs and ROI by monitoring cumulative costs

·    Successfully understanding variability of outsourcing and getting the best deal at the earliest stage

For more information about the summit, please see